本次会议经过充分讨论，以记名投票方式审议通过如下议案： 一、审议通过《关于<公司 2025 年半年度报告及其摘要>的议案》 监事会认为董事会编制和审核公司 2025 年半年度报告的程序符合法律、行 政法规和中国证监会的规定，报告内容真实、准确、完整地反映了公司的实际情 况，不存在任何虚假记载、误导性陈述或者重大遗漏。 表决结果：3 票同意；0 票反对；0 票弃权。 证券代码：300255 证券简称：常山药业 公告编号：2025-34 河北常山生化药业股份有限公司 第六届监事会第三次会议决议公告 本公司及其监事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 河北常山生化药业股份有限公司（以下简称"公司"） 第六届监事会第三 次会议于 2025 年 8 月 22 日在公司办公楼会议室召开。本次会议于 2025 年 8 月 12 日以邮件或直接送达的方式确保每一位监事收到本次会议通知。与会的各位 监事均已知悉与所议事项相关的必要信息。会议应参与表决监事 3 名，实际参与 表决监事 3 名。本次会议由公司监事会主席宗庆松先生主持，符合《公司法》及 《公司章程》等规定。 特此公告 ...

河 河北常山生化药 药业股份有限公 司 2025 年半年度报告全文 河北常山生化 化药业股 股份有限 限公司 2025 年 年半年度 度报告 2025-36 202 25 年 8 月 月 1 河北常山生化药业股份有限公司 2025 年半年度报告全文 第一节重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人高晓东、主管会计工作负责人岳晓华及会计机构负责人(会计 主管人员)岳晓华声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 公司半年度报告涉及未来计划等前瞻性陈述，该计划不构成公司对投资 者的实质承诺，投资者及相关人士均应当对此保持足够的风险认识，并且应 当理解计划、预测与承诺之间的差异。 本公司请投资者认真阅读本半年度报告全文，并特别注意公司在生产经 营中可能存在的政策及行业风险、药品带量采购风险、市场竞争加剧风险、 新产品研发风险等风险，有关风险因素内容与对策举措已在本报告中第三节 "管理层讨论与分析"之"十、公司面临的 ...

证券代码：300255 证券简称：常山药业 公告编号：2025-33 河北常山生化药业股份有限公司（以下简称"公司"）第六届董事会第三次 会议于 2025 年 8 月 22 日在公司办公楼会议室召开。本次会议于 2025 年 8 月 12 日以邮件或直接送达的方式确保每一位董事收到本次会议通知。与会的各位董事 均已知悉与所议事项相关的必要信息。会议应参与表决董事 6 名，实际参与表决 董事 6 名。本次会议由公司董事长高晓东先生主持，符合《公司法》及《公司章 程》等规定。 会议以记名投票方式对各项议案进行表决，审议通过如下议案： 一、审议通过《关于<公司 2025 年半年度报告及其摘要>的议案》 公司《2025 年半年度报告》内容真实、准确、完整地反映了公司 2025 年半 年度的经营情况，不存在虚假记载、误导性陈述或者重大遗漏。具体内容详见公 司同日发布的《2025 年半年度报告》。 公司《2025 年半年度报告》中的财务报告已经公司董事会审计委员会审议 通过。 表决结果：6 票同意；0 票反对；0 票弃权。 二、审议通过《关于制定<信息披露暂缓与豁免管理制度>的议案》 表决结果：6 票同意；0 票反对；0 ...

Market Overview - On August 20, the A-share market saw a rebound with the Shanghai Composite Index, Shenzhen Component Index, and ChiNext Index all reaching new highs for the year. The Shanghai and Shenzhen markets had a total trading volume of 2.41 trillion yuan, a decrease of 180.1 billion yuan from the previous trading day, marking six consecutive days of over 2 trillion yuan in trading volume. Over 3,600 stocks rose in the market [2][3] - The Shanghai Composite Index increased by 1.04% to 3766.21 points, the Shenzhen Component Index rose by 0.89% to 11926.74 points, and the ChiNext Index gained 0.23% to 2607.65 points [3] Sector Performance - Chip stocks surged in the afternoon, while consumer stocks such as liquor rebounded. Consumer electronics also showed active performance. Conversely, high-priced stocks collectively fell, with sectors like film, chemical pharmaceuticals, CRO, and vitamins experiencing declines. The top-performing sectors included liquor, semiconductors, AI glasses, and minor metals, while the worst-performing sectors were film, chemical pharmaceuticals, CRO, and vitamins [2] International Market - In the U.S. stock market on August 20, the Dow Jones Industrial Average rose by 16.04 points (0.04%) to 44938.31 points, while the S&P 500 fell by 15.59 points (0.24%) to 6395.78 points, and the Nasdaq Composite dropped by 142.09 points (0.67%) to 21172.86 points [4][6] - In Europe, the FTSE 100 index increased by 98.92 points (1.08%) to 9288.14 points, while the CAC 40 index in France fell by 6.05 points (0.08%) to 7973.03 points, and the DAX index in Germany decreased by 146.10 points (0.60%) to 24276.97 points [4] Commodity Prices - International oil prices rose on August 20, with light crude oil futures for September delivery increasing by $0.86 (1.38%) to $63.21 per barrel, and Brent crude oil futures for October delivery rising by $1.05 (1.60%) to $66.84 per barrel [5] Automotive Market - According to the China Passenger Car Association, from August 1 to 17, the national retail sales of passenger cars reached 866,000 units, a year-on-year increase of 2%. Cumulatively, retail sales for the year reached 13.611 million units, up 10% year-on-year. The retail sales of new energy vehicles during the same period were 502,000 units, a year-on-year increase of 9% [11] Financial Regulations - The National Financial Regulatory Administration has proposed that the proportion of controlling mergers and acquisitions loans should not exceed 70% of the transaction price, while equity funds must account for at least 30%. This aims to mitigate high-leverage merger financing risks [8] Company Announcements - Muyuan Foods reported a net profit growth of 1170% year-on-year for the first half of the year, while Weicai Technology saw a net profit increase of 831% year-on-year. Tianwei Foods is planning to issue H-shares and list on the Hong Kong Stock Exchange [14]

证券代码：300255 证券简称：常山药业 公告编号：2025-32 | | | | | | 单位：万元 | | --- | --- | --- | --- | --- | --- | | 项目 | 2024 | 年 | 12 31 月 | 日 | | | | | | | （未经审计） | | | 资产总额 | | | 55,944.09 | 50,987.47 | | | 银行贷款总额 | | | 16,344.10 | 11,182.45 | | | 流动负债总额 | | | 18,649.29 | 12,773.25 | | | 负债总额 | | | 23,986.89 | 18,949.21 | | | 或有事项涉及的总额（包括担保、抵押、 | | | | | | | 诉讼与仲裁事项） | | | | | | | 净资产 | | | 31,957.20 | 32,038.27 | | | 项目 | 2024 | 年 | 1 月—12 | 月 | | | | | | | | （未经审计） | | 营业收入 | | | 21,746.68 | | 6,348.74 | | 利润总额 | | | 85.24 ...

Core Viewpoint - Changshan Pharmaceutical announced that as of the date of the announcement, the company and its subsidiaries do not provide guarantees to entities outside the consolidated financial statements, nor do they have overdue guarantees, guarantees involved in litigation, or losses due to judgments against guarantees [1] Summary by Relevant Categories - **Company Guarantees** - The company confirmed that it does not provide guarantees to entities outside the consolidated financial statements [1] - There are no overdue guarantees reported by the company [1] - **Litigation and Losses** - The company stated that there are no guarantees involved in litigation [1] - There are no losses that the company needs to bear due to judgments against guarantees [1]

证券代码：300255 证券简称：常山药业 公告编号：2025-32 河北常山生化药业股份有限公司 关于为全资子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、担保情况概述 河北常山生化药业股份有限公司（以下简称"公司"）于 2025 年 5 月 19 日 召开的 2024 年度股东大会审议并通过《关于提供担保额度预计的议案》，同意公 司为全资子公司河北常山凯库得生物技术有限公司（以下简称"凯库得"）借款 融资提供不超过 3.6 亿元的担保额度，上述额度期限自股东大会审议通过之日起 至 2025 年度股东大会之日。具体内容详见公司刊登于巨潮资讯网的《关于提供 担保额度预计的公告》（公告编号：2025-14）。 本次担保事项在已经审议的年度担保额度范围内，无需再提交公司董事会或 股东大会审议。 三、被担保人基本情况 1．企业名称：河北常山凯库得生物技术有限公司 2．企业类型：有限责任公司 3．注册地址：中国（河北）自由贸易试验区正定片区正定县高新技术产业 开发区北区赵普大街 19 号 4．成立日期：2018 年 02 月 06 日 5 ...

Group 1 - The core point of the article is that the FDA has accelerated the approval of Wegovy (2.4 mg semaglutide) for treating moderate to severe liver fibrosis in adult patients with non-alcoholic steatohepatitis (NASH), leading to significant stock price increases for several pharmaceutical companies [1] Group 2 - Hanyu Pharmaceutical's stock rose over 10% following the news [1] - Companies such as Sunlight Novo and Jinkai Biotechnology saw stock increases of over 5% [1] - Novo Nordisk's stock rose over 6% in after-hours trading in the US market due to the FDA announcement [1]

Core Insights - The market for weight loss drugs is gaining significant attention, with companies like Silverno Pharmaceuticals and others experiencing substantial stock price increases [1][5][11] - Silverno Pharmaceuticals has seen a remarkable IPO performance, with a 5341.66 times oversubscription and a market capitalization exceeding HKD 26 billion [3] - The overall performance of weight loss-related stocks in both Hong Kong and A-share markets has been strong, with several companies reporting over 100% gains this year [5][8] Company Performance - Silverno Pharmaceuticals' core product, Isupaglutide α, has generated revenue of approximately CNY 38.14 million within four months of its launch in China [3] - Other companies like Pag Biopharma and Songli Pharmaceutical have also seen significant stock price increases, with Pag Biopharma rising 32.45% and Songli Pharmaceutical increasing by 13.72% [4][5] - In the A-share market, companies such as Borui Pharmaceutical and Changshan Pharmaceutical have reported gains of 280% and over 100%, respectively [8][10] Market Trends - The global obesity issue is driving the demand for weight loss drugs, positioning this sector as a "golden track" in the pharmaceutical industry [5] - Analysts predict that the GLP-1 drug market could exceed USD 150 billion by 2030, highlighting the potential for domestic oral weight loss drugs [11] - Companies with strong research and sales capabilities are expected to dominate the commercialization of weight loss drugs, with a focus on those with advanced R&D progress [11]

Group 1 - The chemical pharmaceutical sector increased by 2.34% on August 13, with Shouyao Holdings leading the gains [1] - The Shanghai Composite Index closed at 3683.46, up 0.48%, while the Shenzhen Component Index closed at 11551.36, up 1.76% [1] - Notable gainers in the chemical pharmaceutical sector included Shouyao Holdings, which rose by 19.99% to a closing price of 55.94, and Weichip Bio, which increased by 14.39% to 41.18 [1] Group 2 - The chemical pharmaceutical sector saw a net inflow of 342 million yuan from main funds, while retail investors contributed a net inflow of 426 million yuan [2] - Major stocks with significant net inflows included Heng Rui Pharmaceutical with 55.1 million yuan and Fu Xing Pharmaceutical with 23.4 million yuan [3] - Conversely, stocks like ST Sailong and ST Suwu experienced notable net outflows of 4.97% and 3.70%, respectively [2]